Inclusion Body Myositis ,or IBM, is one of many muscle...

Inclusion Body Myositis ,or IBM, is one of many muscle diseases known as inflammatory myopathies, which causes slowly progressing muscular atrophy and weakness(NINDS IBM ,2014,para 1). Let it be known that in this paper, I shall define IBM, give it’s symptoms and signs, as well as whether or not it is related to birth defects, trauma or age related pathology. A prognosis and diagnosis , for said disease, will be given ; as well as , whether or not it is treatable. I will also mention the research being conducted on IBM. Inclusion Body Myositis? Inclusion Body Myositis, or IBM, is a rare inflammatory muscle disease which affects the proximal(near the trunk of the body) and distal(far from the trunk of the body) muscles. It is most evident†¦show more content†¦Some people complain of a loss of balance, this is probably because the muscles become unable to compensate for an off-balance posture. Serious injury from tripping and falling down is a common risk with Inclusion Body Myositis. In addition severe muscle pain is another commonly noted symptom. The diagnosis for IBM, although difficult, simply because the symptoms may be caused by other illnesses, is based on clinical signs and subsequent testing. Many tests can help diagnose the disease , including a blood test that screens for creatine kinase or CK levels. The result of muscle cell damage is the blood enzyme CK. High CK levels would then show strange muscle damage. An electromyography, which is a technique for recording the electrical activity of muscles, can be used to recognize characteristic abnormalities. The best way to diagnose Inclusion Body Myositis , however, is a muscle biopsy, where a small sample of muscle is removed for laboratory analysis (IBM illnessopedia,n.d.,para 3) . Muscle resonance imaging scans may also reveal changes in the muscles. (Travers, P. ,2010, June 17) Prognosis, Treatment and Research The prognosis or outlook for patients suffering from IBM is not good. So far IBM is generally resistant to most therapies. Its rate of progression also seems to be unaffected by available treatments(NINDS IBM ,2014,para 3). According to â€Å"Seminars in Neurology â€Å" IBM